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Abstract
Activation of PKCβ (protein kinase Cβ) plays a critical role in myocardial I/R (ischaemia/reperfusion) injury in
non-diabetic rodents. In the myocardium of diabetes, PKCβ2 overexpression is associated with increased
vulnerability to post-ischaemic I/R injury with concomitantly impaired cardiomyocyte Cav (caveolin)-3 and Akt
signalling compared with non-diabetic rats. We hypothesized that myocardial PKCβ overexpression in diabetes
exacerbates myocardial I/R injury through impairing Cav-3/Akt signalling. Streptozotocin-induced diabetic rats were
treated with the selective PKCβ inhibitor ruboxistaurin (RBX, 1 mg/kg per day) for 4 weeks, starting from 1 week
after diabetes induction, before inducing myocardial I/R achieved by occluding left descending coronary artery
followed by reperfusion. Cardiac function was measured using a pressure–volume conductance system. In in vitro
study, cardiac H9C2 cells were exposed to high glucose (30 mmol/l) and subjected to hypoxia followed by
reoxygenation (H/R) in the presence or absence of the selective PKCβ2 inhibitor CGP41251 (LY533531)Q2
(1 μmol/l), siRNAs of PKCβ2 or Cav-3 or Akt. Cell apoptosis and mitochondrial membrane potential were assessed
by TUNEL (terminal deoxynucleotidyltransferase-mediated dUTP nick-end labelling) and JC-1 staining respectively.
RBX significantly decreased post-ischaemic myocardial infarct size (35 +− 5% compared with 49 +− 3% in control,
P< 0.05) and attenuated cardiac dysfunction, and prevented the reduction in cardiac Cav-3 and enhanced
phosphorylated/activated Akt (p-Akt) in diabetic rats (P< 0.05). H/R increased cardiomyocyte injury under high
glucose conditions as was evident by increased TUNEL-positive and increased JC-1 monomeric cells (P< 0.05
compared with control), accompanied with increased PKCβ2 phosphorylation/activation and decreased Cav-3
expression. Either CGP41251 or PKCβ2 siRNA significantly attenuated all of these changes and enhanced p-Akt.
Cav-3 gene knockdown significantly reduced p-Akt and increased post-hypoxic cellular and mitochondrial injury
despite a concomitant reduction in PKCβ2 phosphorylation. PKCβ2 inhibition with RBX protects diabetic hearts
from myocardial I/R injury through Cav-3-dependent activation of Akt.
Key words: caveolin-3, diabetes, myocardial ischaemia/reperfusion injury, protein kinase Cβ
Abbreviations: ψm, mitochondrial membrane potential; AAR, area at risk; Cav, caveolin; CK-MB, creatine kinase-MB; CO, cardiac output; DMEM, Dulbecco’s modified Eagle’s
medium; dP/dtmax, peak rate of left ventricular pressure increase; dP/dtmin, minimal rate of left ventricular pressure decrease; Ea, arterial elastance; 15-F2t-IsoP, 15-F2t-isoprostane;
HR, heart rate; H/R, hypoxia/reoxygenation; HRP, horseradish peroxidase; I/R, ischaemia/reperfusion; IS, infarct size; LAD, left anterior descending; LDH, lactate dehydrogenase;
LVPmax, maximal left ventricular pressure; mPTP, mitochondrial permeability transition pore; PKC, protein kinase C; PV, pressure–volume; RBX, ruboxistaurin; STZ, streptozotocin; SV,
stroke volume; SW, stroke work; TTC, 2,3,5-triphenyltetrazolium chloride; TUNEL, terminal deoxynucleotidyltransferase-mediated dUTP nick-end labelling.
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INTRODUCTION
Diabetes is associated with significant acute myocardial infarc-
tion, a major cause of heart failure and high mortality rate [1–3].
Many therapeutic strategies that have been effective in the protec-
tion of non-diabetic hearts against I/R (ischaemia/reperfusion) in-
jury lose effectiveness in diabetic states [4–6]. Hyperglycaemia-
induced protein abnormalities, in particular activation of PKC
(protein kinase C), a family of serine/threonine kinases that con-
tribute to myocardial dysfunction [7,8], are potentially respons-
ible for the exacerbation of acutemyocardial infarction in diabetes
[9,10].
PKC comprises a family of ten related serine/threonine
kinases, which are grouped into one of three different subfam-
ilies (classic, novel, and atypical PKC) on the basis of their re-
quirements for Ca2+ for activation. Owing to the coexistence of
multiple PKC isoenzymes in a tissue and lack of PKC isoenzyme-
selective agonists or antagonists, the roles of PKC isoenzymes in
myocardial I/R injury have been elusive. Recently, several studies
have shown that a specific PKCβ inhibitor ruboxistaurin (RBX)
ameliorates I/R injury in various tissues including the heart, in-
testine and lung [11–13], and prevents myocardial hypertrophy
and fibrosis of diabetes [14]. Despite the above important evid-
ence, the role of PKCβ, which is preferably overexpressed in
the myocardium of diabetic rodents, in myocardial I/R injury in
diabetes has not been elucidated.
Our previous research suggests that PKCβ2 requires Cav
(caveolin)-3 for its activation, whereas its overactivation under
diabetic or hyperglycaemic condition inhibits cardiac Cav-3 [8].
Cav-3 is a cardiac-specific caveolin and a membrane structural
protein in caveolae of cardiomyocytes. Cav-3 is key to maintain-
ing the normal structure of cardiomyocyte caveolae and retaining
cardiomyocyte tolerance to I/R injury [15–17]. Our recent study
shows that overexpressed PKCβ2 in diabetic hearts negatively
regulates both Cav-3 expression and the activation of Akt [8], a
major molecule that promotes the survival of cardiomyocytes
through the phosphorylation or inactivation of pro-apoptotic
kinases [18,19], which is associated with impaired cardiac func-
tion and exacerbated post-ischaemicmyocardial I/R injury in dia-
betes [9,20]. The present study aimed to explore whether or not
hyperglycaemia-induced overexpression of PKCβ2, via down-
regulating cardiac Cav-3 and Akt, plays a critical role in exacer-
bating myocardial I/R injury in diabetes and to investigate the
effects and mechanisms of PKCβ2 inhibition on post-ischaemic
myocardial reperfusion injury in diabetes.
MATERIALS AND METHODS
Induction of Type 1 diabetes and roboxistaurin
treatment
Male Sprague–Dawley rats (250+− 10 g, 6–8 weeks of age) were
purchased from the LaboratoryAnimal Service Center at theUni-
versity of Hong Kong. The animals were kept in a temperature-
controlled room with a 12 h light/12 h dark cycle. Experiments
were performed in accordance with the Animal Care Committee
of the University of Hong Kong on the Use of Live Animals in
Teaching and Research (CULATR). Diabetes was induced in rats
by a single tail vein injection of streptozotocin (STZ) (65 mg/kg;
Sigma–Aldrich) dissolved in citrate buffer (0.1 mol/l, pH 4.5)
as described previously [14]. The glucose levels were measured
72 h after STZ injection, and rats were considered diabetic and
used for the study only if they had blood glucose higher than
15 mmol/l. Diabetic rats were then randomized into three groups:
sham-operated (Sham group), untreated control (Con group) and
RBX-treated (RBX group). The rats remained in that particular
group over the ensuing 5 weeks before being subjected to I/R
or sham operation. At 1 week following diabetes induction, rats
in the RBX group were treated with RBX through oral gavage
at 1 mg/kg per day, a dose that was demonstrated to adequately
inhibit PKCβ2 activation in diabetic rat hearts [8,14], whereas
rats in the Sham or Con group received same volume of saline
as vehicle for 4 weeks. We previously found that plasma glucose
levels remained stably high around 1 week after diabetes induc-
tion, whereas insulin levels were low [14]. STZ at a dose of
50–65 mg/kg induces hyperglycaemia at 20–30 mmol/l, but does
not cause severe ketosis even without insulin supplement [21].
Therefore no insulin was given to the diabetic rats in the present
study as we did previously [8,22]. We further found that adminis-
tration of RBX (1 mg/kg per day) starting at 1 week after diabetes
induction for 4 weeks was sufficient to attenuate oxidative stress
and prevent the development of cardiomyopathy in this model
[8]. Thus we used the same protocol as that of our previous study
[8] to induce diabetes and administered RBX.
General characteristics such as water intakes were assessed
on a daily basis, whereas food consumption, body weight and
glucose levels were monitored every week.
Plasma level of free-15-F2t-isoprostane
15-F2t-IsoP (15-F2t-isoprostane), a specific biomarker of oxid-
ative stress and lipid peroxidation in vivo [23], is produced by
oxidation of tissue phospholipids, and was detected by using
a commercial available competition enzyme immunoassay kit
(Cayman Chemical) as described in [9,14]. Plasma samples were
purified using Affinity Column and Affinity Sorbent (Cayman
Chemical) following the manufacturer’s instructions. The assay
relies on the competition between 15-F2t-IsoP in the plasma
(free) and a 15-F2t-IsoP–acetylcholinesterase conjugate (15-F2t-
IsoP tracer) for a limited number of 15-F2t-IsoP-specific rabbit
antiserum-binding sites. The rabbit antiserum-free 15-F2t-IsoP
complex can bind to the rabbit IgG mouse monoclonal antibody
which was previously attached to the well to form a distinct yel-
low colour. The absorbance was assessed under the excitation of
light at 412 nm. The values of free 15-F2t-IsoP were expressed
as pg/ml in plasma samples.
In vivo myocardial ischaemia/reperfusion model
Myocardial I/R injury in vivowas induced by occluding the LAD
(left anterior descending) coronary artery as described previously
[9]. Our previous studies, which used that same rat model, have
demonstrated that hearts from diabetic rats as early as 5 weeks
after diabetes induction are more sensitive to myocardial I/R
injury than hearts from non-diabetic subjects [9,24]. Briefly,
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5 weeks after diabetes induction, diabetic rats were randomly
divided into three groups (n= 8/group): Sham-operated (Sham),
diabetic I/R untreated (Con) and I/R treated with RBX (RBX).
Briefly, sodium pentobarbital-anaesthetized (65 mg/kg) control
and RBX-treated diabetic rats were ventilated and supplemented
with fresh air using a Harvard Apparatus Rodent Respirator at a
rate of 60–70 breaths per min. A left thoracotomy was performed
at the fourth intercostal space and the hearts were suspended in
a pericardial cradle. Then the rats were subjected to 30 min of
coronary occlusion followed by 2 h of reperfusion. Sham rats
received all of the procedures without LAD ligation. At the end
of the 2 h of reperfusion, 5% Evans Blue was intravenously ad-
ministered. The stained region of the heart was identified as the
normal region without I/R episodes. The unstained region was
considered as the area at risk (AAR) [24]. Then, heart tissues
were quickly cut into six 2 mm cross-sectional slices and incub-
ated in 1% TTC (2,3,5-triphenyltetrazolium chloride) buffer for
30 min at room temperature. The heart slices were then fixed
with 10% fresh formalin for 24 h. The area unstained by TTC
was identified as the infarcted tissue. Myocardial IS (infarct size)
was expressed as a percentage of the AAR.
In vivo haemodynamics measurements by PV
(pressure–volume) loop
Left ventricular function in vivo was assessed by PV loops dur-
ing ischaemia and reperfusion as described in [9,24]. Briefly, rats
from Sham, Con and RBX groups were anaesthetized with so-
dium pentobarbital (65 mg/kg), and the right carotid artery and
the left jugular vein in each heart were isolated. A Miller’s poly-
mide 1.9F PV conductance catheter (Scisense) connected to an
Advantage PV control box (Scisense) was gently placed into the
vessel and smoothly advanced into the left ventricle apex un-
til the PV signal was displayed. Then the rats were stabilized
for 15 min before baseline data were recorded. The chest was
opened and the LAD coronary artery was ligated followed by
reperfusion. Saline was given through a plastic tube cannulating
the left jugular vein every 30 min for preventing dehydration. The
haemodynamic cardiac functions recorded in diabetic hearts in-
cludeHR (heart rate), LVPmax (maximal left ventricular pressure),
and load-independent contractility parameters including dP/dtmax
(peak rate of left ventricular pressure increase), dP/dtmin (minimal
rate of left ventricular pressure decrease), SV (stroke volume),
SW (stroke work), CO (cardiac output) (CO=SV×HR) and Ea
(arterial elastance) (Ea=ESP/SV). The data from the haemody-
namic recordings were calculated using PVAN3.2 software.
In situ TUNEL (terminal
deoxynucleotidyltransferase-mediated dUTP
nick-end labelling)
In situ detection of apoptosis was assessed by TUNEL as-
say using an Apoptosis Detection Kit, POD (Roche) according
to the manufacturer’s protocol as described in [22]. Paraffin-
embedded left ventricular tissue blocks were sectioned at 5 mm
and were dewaxed and rehydrated with serial changes of xylene
and ethanol. Proteinase K (20 mg/l) was applied to the section
for 15 min to produce optimal proteolysis. Hydrogen peroxide
(3%) was used to inhibit the endogenous peroxidase. The ter-
minal deoxynucleotidyltransferase reaction was carried out for
1 h at 37 ◦C, and HRP (horseradish peroxidase)-conjugated anti-
digoxigenin was applied at room temperature for 30 min followed
by haematoxylin/eosin staining. The apoptosis in the left vent-
ricle of heart tissue was assessed under light microscopy. Cell
apoptosis was determined as the percentage of apoptotic cells in
all cells.
Plasma CK-MB (creatine kinase-MB) and LDH
(lactate dehydrogenase)
The levels of CK-MB in plasma were determined by rat ELISA
assay (R&D Systems) according to the manufacturer’s instruc-
tions as described previously [9]. The cytoplasmic enzyme CK-
MB reversibly catalyses the reaction of ATP and creatine to form
phosphocreatine and ADP. Increased CK-MB concentration was
used as an index of myocardial cell injury. Briefly, blood samples
from diabetic hearts at the end of the experiments were collected
and assayed in a 96-well plate pre-coated with antibody specific
to CK-MB. After following the manufacturer’s guide, an increase
in the absorbance at a wavelength of 450 nm is an indication of
increased CK-MB in plasma.
The release of the cytoplasmic enzyme LDH is an indicator
of cell death and myocardial injury. LDH in plasma from diabetic
hearts was assessed by using a commercially available Cytotox-
icity Detection Kit (Roche) as described previously [9]. LDH
catalyses the conversion from lactate into pyruvate with con-
comitant transfer of the electrons from NAD to NADH in the
presence of lactate substrate. An increase in colorimetric signal
at a wavelength of 450 nm is an indication of LDH release in
plasma.
Genetic knockdown of PKCβ2 and induction of
hypoxia/reoxygenation in vitro
Cardiac H9C2 cells were cultured in DMEM (Dulbecco’s modi-
fied Eagle’s medium) with 5.5 mmol/l glucose (Gibco Life Tech-
nologies) containing 10% (v/v) FBS as described previously
[22]. When cells reached 50% confluence, 1 μM compound
CGP41251 (Sigma–Aldrich) was added or in alternative studies
scrambled siRNA, PKCβ2 siRNA, Cav-3 siRNA and Akt siRNA
(Santa Cruz Biotechnology) were respectively transfected into
cells according to the manufacturer’s protocol.
At 2 before experiments, the medium was replaced with high-
glucose (30 mmol/l) DMEM containing 10% (v/v) FBS and cells
were cultured for 48 h. After 48 h, the cells were then exposed
to 4 h of hypoxia (1% O2, 5% CO2, 94% N2) in glucose- and
serum-free DMEM followed by 4 h of reoxygenation (H/R) in
high-glucose DMEM containing 10% (v/v) FBS.
Assessment of mitochondrial membrane potential
(ψm) in vitro
Fluorescent images of JC-1 aggregated andmonomeric cells were
measured using a mitochondrial membrane potential assay kit
(Cayman Chemical). In apoptotic cells, the loss of ψm causes
the formation of JC-1 monomeric mitochondria. In healthy cells
with high ψm, JC-1 spontaneously forms complexes known
as JC-1 aggregates. Briefly, H9C2 cells were incubated with
JC-1 working solution for 30 min at 37 ◦C. Then the cells were
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Table 1 General characteristics of rats with STZ-induced diabetes
All values are expressed as means +− S.E.M. n= 8 per group. General parameters including food consumption, water intake,
body weight, plasma 15-F2t-IsoP were measured before and after RBX treatment in diabetic rats (Sham or Con) before
myocardial ischaemia. ∗P< 0.05 compared with before RBX treatment; #P< 0.05 compared with Sham and Con.
Before RBX treatment After RBX treatment
Measurement Sham Con RBX Sham Con RBX
Food consumption (g/kg per day) 86 +− 6 87 +− 5 78 +− 4 128 +− 6∗ 135 +− 5∗ 133 +− 6∗
Water intake (ml/kg per day) 444 +− 25 442 +− 26 438 +− 19 838 +− 26∗ 842 +− 18∗ 800 +− 28∗
Body weight (g) 286 +− 6 270 +− 3 275 +− 5 327 +− 14 317 +− 19 343 +− 9
Plasma glucose (mmol/l) 27 +− 1 25 +− 1 26 +− 1 28 +− 1 27 +− 1 26 +− 1
Plasma 15-F2t-IsoP (pg/ml) 43 +− 4 46 +− 4 50 +− 5 83 +− 5∗ 88 +− 4∗ 54 +− 4#
labelled with DAPI (Vector Laboratories) to counterstain DNA.
The green/red fluorescence ratios were calculated under fluores-
cence microscopy as ratios between JC-1 monomeric cells and
JC-1 aggregates.
Cardiomyocyte apoptotic cell death
In vitro apoptotic cell death was detected using a TUNEL Cyto-
toxicity Detection Kit as described in [25]. Briefly, H9C2 cells
were fixed with 4% (w/v) paraformaldehyde for 30 min at room
temperature. Then the fixed cells were incubated with 0.1% Tri-
ton X-100 for 10 min. After washing cells with PBS, 50 μl of
TUNEL reaction mixture was added, and cells were incubated at
37 ◦C for 1 h. Cells were then washed and labelled with DAPI
to counterstain DNA. The green (TUNEL)/blue (DAPI) fluores-
cence ratios were calculated under fluorescence microscope.
Immunoblotting
Left ventricular tissue was homogenized in protein lysis buf-
fer (20 mM Tris/HCl, pH 7.5, 50 mM 2-mercaptoethanol, 5 mM
EGTA, 2 mM EDTA, 10 mM NaF, 1 mM PMSF, 25 mg/ml leu-
peptin and 2 mg/ml aprotinin). H9C2 cells were lysed by cell lysis
buffer (Cell Signaling Technology) with 1% protease-inhibitor
cocktail (Sigma–Aldrich). The supernatant was collected and
protein concentrations were determined by the Bradford pro-
tein assay (Bio-Rad Laboratories) as described in [14]. Equal
amounts of protein samples (30 μg/lane) were loaded and sep-
arated by SDS/PAGE (8% or 12% gel) and then transferred on
to PVDF membranes (Bio-Rad Laboratories). The membranes
were blocked at room temperature for 1 h with 5% blotting-grade
blocker (Bio-Rad Laboratories) in TBS-T (TBS containing 0.1%
Tween 20 solution). Then themembranes were incubatedwith an-
tibodies against p-PKCβ2, cleaved caspase 3, p-Akt (Ser473), Akt,
β-actin (Cell Signaling Technology), PKCβ2 (Abcam) and Cav-
3 (Santa Cruz Biotechnology) overnight at 4 ◦C. The membranes
were incubated with HRP-conjugated secondary antibodies (Cell
signaling) for 2 h at room temperature. The blots were visualized
using ECL Western blotting detection reagents (GE Healthcare).
ImageJ software (NIH) was used for densitometric analysis of
immunoblots.
Statistical analysis
Data are presented as means+−S.E.M. One- and two-way AN-
OVA were used for statistical analysis (GraphPad Prism) of data
obtained within the same group of rats and between groups of rats
respectively, followed by Tukey’s test for multiple comparisons
of group means. P< 0.05 was considered to indicate statistically
significant differences.
RESULTS
RBX reduced plasma 15-F2t-IsoP in diabetic rats
As shown in Table 1, daily water and food intake were signific-
antly increased in rats with 5-week STZ-induced diabetes com-
pared with that in rats with 1-week diabetes (both P< 0.05).
Body weight gain in rats at 5-week diabetes was not signi-
ficantly different from the body weight in rats with 1 week of
STZ-induced diabetes. Plasma glucose levels reached as high as
27+− 1 mmol/l in the first week and remained stable throughout
the fifth week (28+− 1 mmol/l). The levels of plasma-free 15-F2t-
IsoP in rats with 5-week diabetes were significantly higher than
that in rats with 1-week diabetes. RBX did not change water and
food consumption or body weight, but significantly decreased
plasma levels of 15-F2t-IsoP (P< 0.05) (Table 1).
RBX improved left ventricular function after I/R
injury
Left ventricular function of rats was measured with a PV con-
ductance catheter at baseline, 30 min after ischaemia, and 30,
60 and 120 min after reperfusion. As shown in Figure 1, there
were no significant differences in all cardiac parameters meas-
ured among the three groups at baseline (P< 0.05). Myocardial
ischaemia did not significantly decrease dP/dtmax, LVP, CO, SW,
HR and Ea. However, reperfusion significantly decreased HR,
dP/dtmax, dP/dtmin, LVPmax andEa.All of these I/R injury-induced
impairments in cardiac functions were significantly attenuated or
reversed by RBX (P< 0.05).
RBX reduces post-ischaemic myocardial infarct
size and apoptosis
Figure 2 shows the beneficial effects of RBX on reducing post-
ischaemic myocardial infarct size, TUNEL-positive cells and the
releases of LDH and CK-MB. There were no significant differ-
ences in AAR between groups. Coronary occlusion followed by
reperfusion resulted in 49+− 3% of IS/AAR in Con rats, which
was significantly decreased to 35+− 3% (P< 0.05) by RBX (Fig-
ure 2A). Apoptotic cardiomyocytes in the peri-infarct area were
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Figure 1 Cardiac function measured by pressure–volume loop analysis
(A) HR; (B) dP/dtmax; (C), dP/dtmin; (D), LVPmax; (E) CO; (F) SV; (G) Ea. PV parameters were dynamically measured at
baseline (B), 30 min after ischaemia (I30), and at 30 min (R30), 60 min (R60) and 120 min (R120) after reperfusion.
Diabetic rats were treated with RBX or vehicle (Con) for 4 weeks. At the end of treatment, rats were subjected to 30 min
of ischaemia followed by 120 min of reperfusion. Sham animals underwent all surgical procedures without ischaemia
(Sham). Results are means +− S.E.M. (n= 5 rats per group). ∗P< 0.05 compared with Sham and RBX; #P< 0.05 compared
with Sham.
evaluated by TUNEL staining. The number of TUNEL-positive
cardiomyocytes in the Con group was significantly greater than
in the Sham group (P< 0.05, Figure 2B). The I/R-induced in-
creases in IS and apoptosis were significantly attenuated by RBX
(P< 0.05). Both LDH and CK-MB are the necrotic cell mark-
ers. Myocardial I/R significantly enhanced LDH and CK-MB
concentrations in the plasma of diabetic rats subjected to I/R
compared with rats in the Sham group (P< 0.05, Figures 2C and
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Figure 2 Effects of ruboxistaurin on in vivo myocardial I/R injury
(A) Myocardial infarct size expressed as a percentage of the AAR. The upper panels are the representative cross-sections
COLOUR
of the hearts stained by TTC and Evans Blue from the rats of Sham, Con and RBX respectively. The white area is the infarct
region, the black area is area not at risk, and the red area is the viable myocardium within the AAR. (n= 5 per group). (B) In
situ TUNEL-positive cells expressed as the fold change relative to Sham. Upper panels are the representative left ventricle
section of the hearts stained by TUNEL and haematoxylin/eosin staining from the rats of Sham, Con and RBX respectively.
Apoptotic nuclei are stained dark brown and normal nuclei are stained blue (n= 5 rats per group, magnification ×200,
scale bar, 25 μm). (C) LDH concentration in plasma (n= 5 rats per group). (D) CK-MB concentration in plasma (n= 5 rats
per group). Diabetic rats were treated with RBX or vehicle (Con) for 4 weeks. At the end of treatment, rats were subjected
to ischaemia followed by reperfusion. Sham animals underwent all surgical procedures without ischaemia (Sham). Results
are means +− S.E.M. ∗P< 0.05 compared with Sham; #P< 0.05 compared with Con.
2D), whereas the pre-treatment with RBX significantly decreased
the I/R-induced increases in LDH and CK-MB (P< 0.05).
Effect of RBX on post-ischaemic myocardial protein
expressions of p-PKCβ2, Cav-3, p-Akt and cleaved
caspase 3
Myocardial ischaemia followed by 2 h of reperfusion significantly
increased cardiac p-PKCβ2 expression, but decreased Cav-3 and
p-Akt expression in diabetic rats (allP< 0.05; Figures 3A, 3B andQ3
3C). Myocardial I/R also increased the level of cleaved caspase
3, an active form of caspase 3 (P< 0.05, Figure 3D). The 4-week
RBX pre-treatment could dramatically attenuate I/R induced in-
creases in p-PKCβ2 expression, restore Cav-3 expression and
increase p-Akt expression further in diabetic rats (P< 0.05; Fig-
ures 3A, 3B and 3C).
Genetic knockdown or pharmacological inhibition
of PKCβ attenuated H/R-induced increase in
apoptotic cell death and reduction in ψm
Cardiomyocyte apoptosis was evaluated by TUNEL (Figure 4,
upper row images) and DAPI (Figure 4, lower row images) dual
staining. As shown in Figure 4(A), the number of TUNEL-
positive cells was significantly higher in H/R-stimulated cells
(P< 0.05). This result was largely reduced by a specific PKCβ2
inhibitor, CGP41251, to an extent similar to that in normoxia
group (P< 0.05; Figure 4A). Similarly, PKCβ2 siRNA signi-
ficantly decreased the H/R-induced number of TUNEL-positive
cells to an extent similar to that in normoxia group (P< 0.05;
Figure 4B). Cav-3 or Akt siRNAs under normoxic conditions
significantly increased the number of TUNEL-positive cells
(P< 0.05), which was comparable with that under hypoxic con-
ditions. Both Cav-3 siRNA and Akt siRNA exacerbated H/R-
induced TUNEL-positive cells (P< 0.05; Figures 4C and 4D).
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Figure 3 Effect of ruboxistaurin on myocardial protein expression in vivo
(A) Myocardial p-PKCβ2 expression. Upper panels show representative Western blot bands of p-PKCβ2 and β -actin from
rat hearts of Sham, Con and RBX groups after 30 min of reperfusion. (B) Myocardial Cav-3 expression. Upper panels
show representative Western blot bands of Cav-3 and β -actin from rat hearts of Sham, Con and RBX groups 30 min
after reperfusion. (C) Myocardial p-Akt/Akt expression. Upper panels show representative Western blot bands of p-Akt,
total Akt and β -actin from rat hearts of Sham, Con and RBX groups 30 min after reperfusion. (D) Myocardial cleaved
caspase 3 expression. Upper panels show representative Western blot bands of cleaved caspase 3 and β -actin from rat
hearts of Sham, Con and RBX groups 120 min after reperfusion. Diabetic rats were treated with RBX or vehicle (Con)
and subsequently subjected to ischaemia (I) followed by reperfusion (R). Sham animals underwent all surgical procedures
without ischaemia (Sham). Results are means +− S.E.M. (n= 3 rats per group). ∗P< 0.05 compared with Sham; #P< 0.05
compared with Con.
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Figure 4 Hypoxia/reoxygenation-induced apoptotic cells were reduced by either CGP41251 (CGP) or PKCβ2 siRNA, but
increased by either Cav-3 siRNA or Akt siRNA
(A) PKCβ2 inhibitor CGP41251 reduced H/R-induced apoptotic cells. Upper panels are representative fluorescent images
COLOUR
of TUNEL and DAPI staining cells from Nor, CGP, H/R and H/R+CGP groups. Apoptotic cells are expressed as a percentage
of TUNEL-positive nuclei of DAPI-positive nuclei. TUNEL-positive apoptotic nuclei show green fluorescence. DAPI-positive
normal nuclei show blue fluorescence. (B) Knockdown of PKCβ2 reduces H/R-induced apoptotic cells. Upper panels show
representative fluorescent images of TUNEL and DAPI staining cells from Nor, PKCβ2 siRNA, H/R and H/R+PKCβ2 siRNA
groups. (C) Knockdown of Cav-3 increases H/R-induced apoptotic cells. Upper panels show representative fluorescent
images of TUNEL and DAPI staining cells from Nor, Cav-3 siRNA, H/R and H/R+Cav-3 siRNA groups. (D) Knockdown of
Akt increases H/R-induced apoptotic cells. Upper panels show representative fluorescent images of TUNEL and DAPI
staining cells from Nor, Akt siRNA, H/R and H/R+Akt siRNA groups. H9C2 cells were exposed to high glucose for 48 h
and subsequently treated with CGP or PKCβ2, Cav-3 or Akt siRNA for 24 h. Then the cells were exposed to 4 h of hypoxia
followed by 4 h of reoxygenation (H/R). Normoxia cells underwent normal oxygen (Nor). Results are means +− S.E.M. (n= 5
per group, magnification ×100, scale bar, 12.5 μm). ∗P< 0.05 compared with Nor; #P< 0.05 compared with H/R.
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The variations in apoptotic cell death assessed by DAPI staining
mirrored thosemeasured by TUNEL staining (results not shown).
Mitochondrial damage was measured using a mitochondrial
membrane potential kit. The increase in the number of JC-1
monomeric cells reflected the loss of ψm. Compared with nor-
moxia cells, the number of JC-1monomeric cells was remarkably
increased in H/R-stimulated cells (P< 0.05). The H/R-induced
increase in monomeric form cells were reduced by CGP41251
to the extent of that in normoxia cells (P< 0.05; Figure 5A).
Similarly, PKCβ2 siRNA significantly reduced the H/R-induced
JC-1 monomeric cells to an extent similar to that in normoxia
cells (P< 0.05; Figure 5B). Both Cav-3 siRNA and Akt siRNA
under normoxic conditions significantly increased JC-1 mono-
meric cells (P< 0.05) to an extent similar to that under hypoxic
conditions. Both Cav-3 siRNA and Akt siRNA exacerbated H/R-
induced monomeric cells (P< 0.05; Figures 5C and 5D).
Protein expression of p-PKCβ2, Cav-3, p-Akt and
cleaved caspase 3 following H/R and PKCβ2 or
Cav-3 gene knockdown
Protein expression of p-PKCβ2, Cav-3, p-Akt and cleaved cas-
pase 3 in H9C2 cells were measured by Western blotting. As
shown in Figure 6(A), Knockdown of PKCβ2 with siRNA atten-
uated p-PKCβ2 expression by 23% in the normoxia group and
by 29% in the hypoxia group (P< 0.05). Knockdown of Cav-3
reduced p-PKCβ2 expression by 40% in the normoxia group
and by 42% in the hypoxia group (P< 0.05; Figure 6B). Cav-
3 expression was lower in H/R-stimulated cells compared with
normoxia cells. This reduction was restored by PKCβ2 siRNA in
both the normoxia and the hypoxia group (P< 0.05; Figure 6C).
Cav-3 siRNA suppressed Cav-3 expression by 68% under nom-
oxic conditions, and by 40% under hypoxic conditions (P< 0.05;
Figure 6D). p-Akt expression was significantly increased in H/R-
stimulated cells. PKCβ2 siRNA remarkably increased, but Cav-
3 siRNA decreased, p-Akt expression (P< 0.05; Figure 6E).
Cleaved caspase 3 expression was decreased by PKCβ2 siRNA,
but increased by Cav-3 siRNA (P< 0.05; Figure 6F).
DISCUSSION
In the present study, we demonstrated the protective effects of
RBX, a selective PKCβ2 inhibitor at the dosage used [14], on
acute myocardial I/R injury in rats with STZ-induced diabetes,
and the role of the Cav-3/Akt pathway in PKCβ inhibition me-
diated protection against post-ischaemic and post-hypoxic cardi-
omyocyte injury.We found that (i) I/R induced significant cardiac
dysfunction and myocardial infarction in diabetic rats, which was
accompanied by increased protein expression of phosphorylated
PKCβ2 and down-regulatedCav-3; (ii) RBXadministration start-
ing at the onset of diabetes for 4 weeks conferred cardioprotection
through specific inhibition of PKCβ2, and restoration of Cav-3
and phosphorylated Akt; (iii) PKCβ2 gene knockdown attenu-
ated the increase in H/R-induced apoptotic cardiomyocyte death
and restored ψm through up-regulation of Cav-3 and phos-
phorylated Akt in high-glucose-exposed cardiomyocytes; (iv)
Cav-3 gene knockdown caused apoptotic cardiomyocyte death
and exacerbated H/R-induced cardiomyocyte and mitochondrial
injury by decreasing phosphorylated Akt. To our knowledge, the
present study provides the first evidence that RBX ameliorates
myocardial I/R injury via a PKCβ2-dependent mechanism, and
the cardioprotection of RBX is achieved at least in part through
Cav-3/Akt-mediated mitochondrial pathway.
Myocardial infarction and dysfunction are the major as-
sessments of I/R injury in vivo [26–28]. RBX has previously
been shown to have beneficial effects on microvascular dys-
function in diabetic hearts [29–32], and has a post-ischaemic
infarction-limiting effect in non-diabetic hearts [33]. However,
the cardiomyocyte-specific effect of RBX on I/R injury in dia-
betic rodents has not been studied. In the present study, chronic
RBX administration in diabetic rat hearts sufficiently reduced
infarct size by 29% (Figure 2A), and apoptosis by 22.2% (Fig-
ure 2B). In addition, RBX improved cardiac contractile function
by preserving dP/dtmax and dP/dtmin, two indices of contractility
(Figure 1B and 1C) with concomitant reduction of plasma levels
of CKMB and LDH, markers of cardiomyocyte cellular injury
(Figure 2C and 2D). These results suggest that PKCβ activation
plays detrimental roles in diabetes during I/R injury. However, we
did not observe significantly beneficial effects of RBX on cardiac
function at baseline or ischaemia. This may be due to the delayed
administration of RBX (1 week after diabetes induction) that may
have allowed some of the early adverse effects of diabetes to de-
velop. We could not exclude the possibility that administration
of RBX immediately at the onset of diabetes could largely im-
prove cardiac function. The beneficial effect of RBX may due to
its ability to prevent oxidative stress and delay the progression
to myocardial dysfunction and remodelling. Our previous study
provides evidence that RBX processes antioxidant properties, at-
tenuates hyperglycaemia-induced oxidative stress, and preserves
diastolic function of diabetic hearts [14]. Several studies have
also supported the antioxidant capacity of RBX during I/R injury
[11,34] and diabetes [8,14]. In line with our previous studies, we
showed that RBX treatment significantly reduced plasma levels
of 15-F2t-IsoP (Table 1), a specific index of oxidative stress.
Reduction of the hyperglycaemia-mediated increase in oxidative
stress should be a potential mechanism whereby RBX attenuates
post-ischaemic myocardial infarction in diabetes, given that, in
the same in vivo I/R model in type 1 diabetic rats, we were able to
show that effective antioxidant treatments applied for 4 weeks be-
fore inducing I/R to reduce plasma 15-F2t-IsoP can significantly
reduce post-ischaemic myocardial infarction [22,24], as seen in
the present study. In the present study, we, for the first time,
demonstrate that RBX has the potential to attenuate the early
phrase of post-ischaemic myocardial I/R injury in diabetes, al-
though the longer-term cardioprotective effects in diabetes such
as post-ischaemicmyocardial remodelling have not yet been stud-
ied.
The mechanisms by which RBX protect hearts from I/R in-
jury are not well understood. Although aberrant cell apoptosis
has been shown to play crucial roles in the pathogenesis of
myocardial infarction and dysfunction [35–37] in normal hearts,
its role in diabetic hearts during I/R has not been studied. Dis-
tinct from necrosis, which is mainly associated with cell swelling
C© The Authors Journal compilation C© 2015 Biochemical Society 9
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Figure 5 Hypoxia/reoxygenation-induced JC-1 monomeric mitochondria were reduced by either CGP41251 (CGP) or
PKCβ2 siRNA, but increased by either Cav-3 siRNA or Akt siRNA
(A) Inhibition of PKCβ2 with CGP reduced H/R-induced JC-1 monomeric mitochondria. Upper panels show representative
COLOUR
fluorescent images of JC-1 monomeric mitochondria showing green fluorescence and JC-1 aggregated mitochondria show-
ing intense red fluorescence from Nor, CGP, H/R and H/R+CGP groups. (B) PKCβ2 knockdown reduced H/R-induced JC-1
monomeric mitochondria. Upper panels show representative fluorescent images of JC-1 monomeric and aggregated mito-
chondria from Nor, PKCβ2 siRNA, H/R and H/R+ PKCβ2 siRNA groups. (C) Cav-3 gene knockdown increased H/R-induced
JC-1 monomeric mitochondria. Upper panels show representative fluorescent images of JC-1 monomeric and aggregated
mitochondria from Nor, Cav-3 siRNA, H/R and H/R+Cav-3 siRNA group. (D) Akt knockdown increased H/R-induced JC-1
monomeric mitochondria. Upper panels show representative fluorescent images of JC-1 monomeric and aggregated mito-
chondria from Nor, Akt siRNA, H/R and H/R+Akt siRNA groups. H9C2 cells were exposed to high glucose and subsequently
treated with CGP or PKCβ2, Cav-3 or Akt siRNA. Then the cells were exposed to hypoxia followed by reoxygenation (H/R).
Normoxia cells underwent normal oxygen (Nor). Results are means +− S.E.M. (n= 5 per group, magnification ×100, scale
bar, 12.5 μm). ∗P< 0.05 compared with Nor; #P< 0.05 compared with H/R.
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Figure 6 Effect of the siRNA of PKCβ2, Cav-3 or Akt on cardiomyocyte protein expression in vitro
(A) Effect of PKCβ2 knockdown on p-PKCβ2 and PKCβ2 protein levels in high-glucose-exposed cardiac cells. (B) Effect of
Cav-3 knockdown on p-PKCβ2 and PKCβ2 protein expression. (C) Effect of PKCβ2 knockdown on Cav-3 protein levels. (D)
Effect of Cav-3 knockdown on Cav-3 protein expression. (E) Effect of PKCβ2 or Cav-3 knockdown on p-Akt/Akt expression.
(F) Effect of PKCβ2 or Cav-3 knockdown on cleaved caspase 3 expression. H9C2 cells were exposed to high glucose and
subsequently treated with PKCβ2, Cav-3 or Akt siRNA. Then the cells were exposed to hypoxia followed by reoxygenation
(H/R). Normoxia cells underwent normal oxygen (Nor). Results are means +− S.E.M. (n= 3 per group). ∗P< 0.05 compared
with Nor; #P< 0.05 compared with H/R.
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and inflammation, apoptosis is a programmed cell death that in-
volves DNA fragmentation and activation of caspase family, in
particular caspase 3, which can in turn activate DNA degrada-
tion leading to cell death. In the present study, RBX signific-
antly attenuated DNA fragmentation as was evident by increased
TUNEL-positive cells (Figure 2B) and activated/cleaved caspase
3, markers of cell apoptosis (Figure 3D) in the myocardium of
diabetic rats. Additionally, using high-glucose-stimulated cardiac
cells, we demonstrated that inhibition of PKCβ2 with siRNA or
CGP41251 attenuated the hyperglycaemia-induced increase in
TUNEL-positive cells (Figure 4B) and activated/cleaved caspase
3 (Figure 6F). Our in vivo and in vitro data strongly suggest that
increased PKCβ2 activation plays a critical role in exacerbating
cardiomyocyte apoptosis, a major form of cardiomyocyte death
following ischaemia/hypoxia under hyperglycaemic conditions.
Hyperglycaemia increased the interaction of Cav-3 with
PKCβ2 on lipid rafts. Following PKCβ2 activation, PKCβ2
translocates from the cytosol to the cell membrane where it in-
creases its association with Cav-3 in cardiomyocytes [8]. This
process may increase the damage of cell membranes due to the
decrease in Cav-3 levels in lipid rafts caused by hyperglycaemia
[8]. Despite the findings regarding the alterations of Cav-3 in
diabetic hearts, the role of Cav-3 in PKCβ2 activation and ap-
optosis in post-ischaemic myocardial injury has not been ex-
amined. We found that RBX down-regulated cardiac Cav-3 in
diabetic myocardium (Figure 3B). In in vitro study, we confirmed
that PKCβ2 gene knockdown and inhibition increased the post-
ischaemicCav-3 expression (Figure 6C). In contrastwith PKCβ2,
knockdown of Cav-3 enhanced cell apoptosis (Figures 4C and
6F), but concomitantly reduced PKCβ2 phosphorylation (Fig-
ure 6B), which indicated that Cav-3 is a salvage molecule for
cardiomyocyte survival and the basal level of Cav-3 is required
for PKCβ2 activation. Akt is a well-established cardioprotect-
ive molecule for cell survival during I/R injury [24,38]. In the
present study, RBX enhanced phosphorylated Akt, although Akt
phosphorylationwas not significantly altered following I/R in dia-
betic myocardium (Figure 3C). In high-glucose-exposed cardiac
cells, we observed the decreased phosphorylated Akt follow-
ing H/R, whereas PKCβ2 siRNA enhanced p-Akt levels (Fig-
ure 6E). The difference of this result may be partially due to
the experimental complicity in in vivo and in vitro study includ-
ing the duration of diabetes, degree of ischaemia and reperfu-
sion that may differentially contribute to p-Akt expression in the
heart.
The consequence of abnormal signalling transduction induced
by I/R is the mPTP (mitochondrial permeability transition pore)
opening and depolarization of the ψm to increase cell death.
The mPTP opening results in loss of ψm, uncoupling of res-
piratory chain, Ca2+ accumulation, release of cytochrome c and
free radicals, and mitochondrial swelling [39–42]. As shown in
Figures 5(A) and 5(B), the ψm was regulated by PKCβ2 as
was evident as a lower number of JC-1 monomeric cells after
pharmacological inhibition or genetic knockdown of PKCβ2.
Cav-3 and Akt are both required for the PKCβ2-mediated pro-
tection against mitochondrial dysfunction, as both Cav-3 and Akt
siRNA significantly increased JC-1 monomeric cells in the H/R
group (Figures 5C and 5D).
In summary, the present study demonstrates that RBX ameli-
orates myocardial I/R injury by attenuating post-ischaemic
myocardial infarction and dysfunction. The plausible mechan-
ism underlying the cardioprotection of RBX is via Cav-3/Akt-
mediated attenuation of post-hypoxic mitochondrial injury.
CLINICAL PERSPECTIVES
 This study may have high translational potential given that
ruboxistaurin has now been approved by the U.S. FDA (Food
and Drug Administration) for clinical trials to treat diabetic
peripheral neuropathy.
 Our findings that ruboxistaurin, as an oral PKCβ inhib-
itor with antioxidant properties that can attenuate post-
ischaemic myocardial infarction and dysfunction in function-
ally impaired hearts of diabetic rodents, strongly suggest that
ruboxistaurin may have great potential to prevent the devel-
opment of ischaemic heart diseases in patients with diabetes,
especially when antioxidants or other medications are not clin-
ically effective at clinical settings nowadays.
 Meanwhile, the mechanisms identified as being involved in
ruboxistaurin-induced cardioprotection may help in the de-
velopment of strategies to improve the prognoses of acute
myocardial infarction after surgery such as revascularization
in patients with diabetes.
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